Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial is evaluating the efficacy and safety of subcutaneous Efgartigimod PH20 (efgartigimod alfa) in adults with active idiopathic in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antisynthetase Syndrome
• Dermatomyositis
• Idiopathic Inflammatory Myopathy
• Immune-mediated Necrotizing Myopathy
• Myositis
• Polymyositis

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Active Idiopathic Inflammatory Myopathy, Myositis | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING